Quarterly ResultMay 6, 2026, 04:13 PM
Zevra Q1 Revenue +78% to $36.2M; Net Income $37.9M; SDX Portfolio Sold
AI Summary
Zevra Therapeutics reported strong financial results for the first quarter ended March 31, 2026, with net revenue increasing 78% year-over-year to $36.2 million and achieving a net income of $37.9 million. The company also completed the $50.0 million sale of its SDX portfolio and fully repaid its $63.1 million term loan, significantly strengthening its financial position. Operational progress included continued performance for MIPLYFFA and advancement in the Phase 3 DiSCOVER trial for Vascular Ehlers-Danlos Syndrome.
Key Highlights
- Q1 2026 net revenue increased 78% to $36.2 million compared to Q1 2025.
- Reported Q1 2026 net income of $37.9 million, or $0.62 per basic share.
- Completed $50.0 million sale of SDX portfolio to Commave Therapeutics.
- Prepaid the $63.1 million term loan in full, achieving a debt-free balance sheet.
- Cash, cash equivalents, and securities stood at $236.8 million as of March 31, 2026.
- MIPLYFFA net revenue was $24.6 million for Q1 2026.
- Enrolled 10 patients in the Phase 3 DiSCOVER trial for VEDS in Q1 2026, totaling 62 patients.